Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.
- 10 patients showed clinically significant depression symptom reduction
- Program backed by private health funding and regulatory support
- Treatment delivered across four Empax clinics with a fifth opening soon
- Data presented at 2026 International Mental Health Conference
- Early results are exploratory with a small sample size
Early Cohort Shows Statistically Significant Symptom Improvements
Emyria Limited (ASX:EMD) has unveiled promising early outcomes from its second major treatment program targeting treatment-resistant depression (TRD). In a cohort of 10 patients, all showed statistically significant improvements across four standard mental health measures, with average depression symptom scores falling from 16.8 to 10.0 on the QIDS-SR16 scale, a clinically meaningful 6.8-point reduction. This group comprises individuals who had not responded adequately to conventional therapies, highlighting the potential impact of Emyria’s approach.
Expanding Beyond PTSD to Address a Large Unmet Need
Building on its established PTSD program, Emyria is extending its psychedelic-assisted therapy model to TRD, a condition affecting roughly one in three of the two million Australians living with depression. The program is delivered through Emyria’s national Empax Centre network, currently operating in four clinics with a fifth slated to open in New South Wales in Q3 2026. This expansion taps into a significant patient population underserved by existing treatments.
Growing Support from Health Funders and Regulators
Most patients in the TRD program are supported by private health insurance or other funding sources, indicating increasing system acceptance of these novel therapies. Regulatory progress has also been notable: in May 2026, the Therapeutic Goods Administration broadened its Authorised Prescriber pathway to include a wider range of clinicians eligible to deliver psychedelic-assisted therapies. This regulatory refinement aims to accelerate patient access and workforce capacity, a move that aligns with Emyria’s clinic expansion plans and growing national footprint.
Limitations Temper Early Optimism
While the initial data are encouraging, Emyria cautions that the findings are preliminary. The small sample size means that results could be influenced by individual patient variability. Additionally, follow-up periods ranged from 3 to 14 months post-treatment, introducing timing inconsistencies in outcome measurement. The 10 patients assessed represent an early subset of over 20 currently enrolled, with more comprehensive data expected as the program scales.
Presentation and Future Prospects
Chief Scientific Officer Dr Michael Winlo will present these findings at the International Mental Health Conference on the Gold Coast on 24 June 2026, underscoring Emyria’s commitment to sharing real-world data and refining care models. The company’s integrated approach combines clinical services with data-driven therapy development, positioning it at the forefront of innovative mental health treatments in Australia.
Bottom Line?
Emyria’s early TRD results offer a hopeful glimpse but hinge on broader data and sustained regulatory momentum.
Questions in the middle?
- How will outcomes evolve as larger patient cohorts complete the TRD program?
- What impact will expanded clinician eligibility have on treatment accessibility?
- Can health funders maintain or increase support as the program scales nationally?